<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3-6057-25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XANAX 1 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALPRAZOLAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        13.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANICO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANICO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 5165]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Viatris Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Viatris Healthcare
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05BA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance of Xanax is alprazolam. Xanax belongs to a group of medicines called benzodiazepines (medicines that relieve anxiety).</p><p>Xanax tablets are used in adults for the treatment of symptoms of anxiety that are severe, crippling or that cause the patient great distress. This medicine is only intended for short-term use.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Xanax:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to alprazolam, to benzodiazepines or to any of the other ingredients of this medicine listed in section 6.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from severe muscle weakness (myasthenia gravis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe breathing difficulties.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe sleep dyspnoea syndrome.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Xanax:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from glaucoma.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are depressed, as treatment with Xanax can increase the risk of developing suicidal thoughts or self-harm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phases of hypomania and mania (excessive activity and abnormal state of excitation) were reported in the context of alprazolam use in depressive patients.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; benzodiazepines and related products should be used with caution in the elderly as the sedative and/or muscle relaxant effect may contribute to falls, with often serious consequences in this population.</p><p>The concomitant use of alcohol can intensify the effect of benzodiazepines, especially stupor. Therefore, consuming alcohol is advised against while taking Xanax.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Alprazolam is not recommended for children and adolescents under the age of 18 years.</p><p>&nbsp;</p><p><strong>Other medicines and Xanax</strong></p><p>Benzodiazepines, such as alprazolam, additionally have a suppressive effect on the central nervous system (CNS) if taken together with other psychotropics, antiepileptics (medicines for convulsions), antihistamines (medicines for allergies), alcohol and other medicines affecting the CNS.</p><p>&nbsp;</p><p>The following medicines can increase the effect of alprazolam:</p><ul><li>ketoconazole, itraconazole or other azole antifungal medicines (for infections caused by fungi). Concomitant use is therefore not indicated.</li><li>nefazodone, fluvoxamine, fluoxetine (used to treat depression), dextropropoxyphene (strong painkiller), sertraline, oral contraceptives, diltiazem (used to treat high blood pressure), macrolide antibiotics such as erythromycin and clarithromycin, cimetidine (used to reduce the production of acid in the stomach).</li></ul><p>&nbsp;</p><p>The following medicines may reduce the effect of alprazolam:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, phenobarbital, phenytoin (used to treat epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (used to treat tuberculosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&#39;s wort (a herbal medicine used to treat depression).</p><p>&nbsp;</p><p>Tell your doctor if you are taking digoxin (used to treat heart failure), as it may be necessary to adjust the dose of Xanax or to start frequent monitoring.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Xanax with food, drink and alcohol</strong></p><p>Alcohol can intensify the effect of benzodiazepines, especially stupor. You must therefore not drink alcohol during treatment with Xanax.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. The use of benzodiazepines during pregnancy and breast-feeding is advised against.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Because benzodiazepines may affect your ability to react (in particular your reaction time), driving and using certain tools or machines are advised against.</p><p>&nbsp;</p><p><strong>Xanax 0.5 mg and 1 mg contains aluminium. </strong></p><p>If you are allergic to aluminium, do not take Xanax 0.5 mg and 1 mg tablets. Other Xanax tablets contain no aluminium.</p><p><strong>&nbsp;</strong></p><p><strong>Xanax contains lactose. </strong></p><p>Talk to your doctor before taking Xanax if you know that you have a sugar intolerance.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>At the beginning of the treatment you may feela little sleepy, which usually decreases when continuing treatment. Ask your doctor for advice if this effect should occur.</p><p>&nbsp;</p><p>SYMPTOMATIC TREATMENT OF ANXIETY</p><p>The recommended dose (quantity) for patients older than 18 years is 0.25 mg to 0.5 mg three times per day, up to a maximum of 4 mg per day.</p><p>The dose must be reduced to the lowest effective dose possible, especially in elderly and weak patients, for example 0.25 mg two to three times per day.</p><p>&nbsp;</p><p>Always follow your doctor&rsquo;s instructions carefully.</p><p>If you have additional questions regarding the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p><em>Duration of treatment</em>:</p><p>The risk of dependence or abuse may increase with the dose and duration of treatment. Therefore, the doctor will prescribe the lowest effective dose for the shortest duration and will regularly reassess the need to continue with treatment (see section 2 &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>The maximum duration of treatment should not exceed 2 to 4 weeks. Long-term treatment is not recommended.</p><p>&nbsp;</p><p>Your doctor will tell you how long you must take Xanax. Do not prematurely discontinue the therapy.</p><p>&nbsp;</p><p><strong>If you take more Xanax than you should</strong></p><p>If you take more Xanax than you should, contact your doctor, your pharmacist or the poison control centre immediately. Do not give the patient anything to drink if he or she is not completely conscious.</p><p>&nbsp;</p><p>INFORMATION FOR THE DOCTOR</p><p>In the case of severe intoxication with coma or respiratory failure flumazenil can be administered intravenously as an antidote.</p><p>The use of flumazenil as an antidote is contraindicated in the following cases:</p><p>- when using tricyclic antidepressants</p><p>- in case of concomitant use of medicines triggering convulsions</p><p>- with anomalies in the ECG, e.g. a prolonged QRS complex or QT interval (which give rise to the suspicion of concomitant use of tricyclic antidepressants).</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Xanax</strong></p><p>If you forget to take a dose at the usual time, take it as soon as you remember unless it is time for your next dose. In this case skip the forgotten dose and continue the treatment as usual. Do not take a double dose if you have forgotten the previous one.</p><p>&nbsp;</p><p><strong>If you stop taking Xanax</strong></p><p>Do not suddenly discontinue the treatment as the dose needs to be reduced gradually, after consultation with your doctor. If you suddenly discontinue treatment, withdrawal symptoms such as bad mood, insomnia, cramps, nausea, sweating, convulsions and delirium may occur, especially in patients receiving high-dose treatment.</p><p>&nbsp;</p><p>Therefore, your doctor will gradually reduce the dose at the end of treatment. The dose reduction will be worked out on an individual basis, as gradually stopping treatment depends on numerous factors (e.g., duration of treatment and your daily dose). Ask your doctor how to gradually reduce your dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The following side effects were associated with alprazolam treatment in patients participating in controlled clinical trials and those which have been reported post-marketing (*):</p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sedation (falling asleep), somnolence, loss of the ability to coordinate movements, impaired memory, impaired speech (dysarthria), dizziness, headaches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue, irritability</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, disorientation, reduced libido, anxiety, insomnia, nervousness, increased libido</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; balance disorders, coordination disorders, concentration disorders, abnormal need to sleep (hypersomnia), lethargy (extensive weakness), tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin infection (dermatitis)*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sexual dysfunction*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss, weight gain</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mania* (excessive activity and abnormal excitation) (see section 2: Warnings and precautions), hallucinations*, &nbsp;anger*, agitation*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amnesia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; incontinence*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; menstrual irregularity*</p><p>&nbsp;</p><p><strong>Side effects with unknown frequency:</strong></p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>autonomic nervous system disorders*, </em>impaired muscle tone (dystonia)*</p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>angioedema*</em></p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>photosensitivity<em>*</em></p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>increased <em>prolactin production*</em></p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>hypomania*, aggressiveness*, hostility*, abnormal thoughts*, psychomotor hyperactivity*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal disorders*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (hepatitis)*, liver dysfunction*, jaundice*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary retention*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased intraocular pressure*</p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>peripheral oedema*</p><p>&nbsp;</p><p>The following side effects were also reported:</p><p>&nbsp;</p><p><strong>Rare side effects (may affect up to 1 in 1000 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cholestasis (reduced biliary secretion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agranulocytosis (lack of certain white blood cells in the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory depression in patients who suffer from unspecific, chronic respiratory disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions or severe, potentially life-threatening, allergic reactions (anaphylaxis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sporadic deviation of ovulation abnormalities and increased breast volume</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anorexia (loss of appetite)</p><p>&nbsp;</p><p>The following side effects of benzodiazepines were reported very rarely or very extraordinarily: fatigue, indications of paranoia, psychological and physical dependence, withdrawal symptoms (headaches, muscle pain, extreme anxiety, irritability, feeling of unreality (derealisation), depersonalization (loss of physical or mental reality), reduced hearing, stiffness and prickling in the extremities, hypersensitivity to noise and physical contact, epileptic seizures).</p><p>Withdrawal symptoms (&ldquo;rebound&rdquo; phenomena) such as insomnia and anxiety as well as mood swings, anxiety, sleep disorders and agitation may occur when discontinuing treatment.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side affects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:343px"><tbody><tr><td style="vertical-align:top; width:340px"><p>The National Pharmacovigilance Center (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> </strong><strong>GCC States</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 25 &deg;C.</p><p>Do not use Xanax after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Shelf life: 36 months.</p><p>Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active ingredient is alprazolam. One tablet contains 0.25 mg, 0.5 mg or 1 mg of alprazolam.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: lactose, microcrystalline cellulose, colloidal anhydrous silica, maize starch, magnesium stearate and docusate sodium (85%) with sodium benzoate (15%) powder, erythrosine (E127) as aluminium lake (only in 0.5 mg and 1 mg tablets) and indigo carmine (E132) as aluminium lake (only in 1 mg tablets).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Xanax tablets are available in the form of:
	white, scored tablets with 0.25 mg in an elliptic oval shape: packs with 50 tablets. 
	pink, scored tablets with 0.5 mg in an elliptic oval shape: packs with 50 tablets. 
	lavender, scored tablets with 1 mg in an elliptic oval shape: packs with 30 tablets. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder: </strong></p><p>Upjohn SRL, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium.</p><p><strong>Manufacturer: </strong></p><p>Sanico N.V., Belgium</p><p><strong>Packed and Released by:</strong></p><p>Pfizer Italia S.r.l., Ascoli Piceno, Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في زاناكس هي ألبرازولام. ينتمي زاناكس إلى مجموعة من الأدوية تسمى مركبات البنزوديازيبين (أدوية تخفف القلق).</p><p dir="RTL">يستخدم أقراص زاناكس البالغون لعلاج أعراض القلق الشديدة أو المعوقة أو التي تسبب ضيقًا بالغًا للمريض. هذا الدواء مخصص للاستخدام قصير الأمد فقط.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال زاناكس:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه ألبرازولام، أو تجاه مركبات البنزوديازيبين، أو تجاه أي من المكونات الأخرى لهذا الدواء المدرجة في القسم ٦.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ضعف شديد في العضلات (الوهن العضلي الوبيل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من صعوبات شديدة في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمتلازمة ضيق التنفس الشديد أثناء النوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات شديدة في الكبد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات عند استعمال زاناكس</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول زاناكس:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الزرق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالاكتئاب، لأن العلاج بزاناكس يمكن أن يزيد خطر التعرض لأفكار الانتحارية أو إيذاء النفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبلغ عن حدوث مراحل من الهوس الخفيف والهوس (نشاط مفرط وحالة استثارة غير طبيعية) في سياق استخدام ألبرازولام مع المرضى المصابين بالاكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي توخي الحذر عند استخدام مركبات البنزوديازيبين والمنتجات ذات الصلة مع كبار السن لأن التأثير المهدئ للعضلات أو المرخي للعضلات أو كليهما قد يساهما في حدوث حالات سقوط غالبًا ما تنجم عنها عواقب خطيرة في هذه الفئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يزيد استخدام المتزامن للكحوليات حدة تأثير مركبات البنزوديازيبين، وخصوصًا الذهول. لذلك لا ينصح بتناول الكحوليات أثناء تناول زاناكس.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى باستخدام ألبرازولام مع الأطفال والمراهقين الذين تقل أعمارهم عن ١٨ عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية.</strong></p><p dir="RTL">تسبب مركبات البنزوديازيبين، مثل ألبرازولام، تأثيرًا إضافيًا كابتًا للجهاز العصبي المركزي (CNS) في حالة تناولها بالتزامن مع المركبات الأخرى نفسية التأثير، ومضادات الصرع (أدوية لعلاج نوبات الاختلاج)، ومضادات الهيستامين (أدوية لعلاج الحساسية)، والكحوليات، والأدوية الأخرى التي تؤثر على الجهاز العصبي المركزي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تزيد الأدوية التالية من تأثير ألبرازولام:</p><ul><li dir="RTL">كيتوكونازول، أو إيتراكونازول، أو الأدوية الآزولية الأخرى المضادة للفطريات (لعلاج حالات العدوى التي تسببها الفطريات). لذلك، لا يوصى باستخدام المنتج بالمتزامن معها.</li><li dir="RTL">نيفازودون، فلوفوكسامين، فلوكسيتين (المستخدمة لعلاج الاكتئاب)، ديكستروبربوكسيفين (مسكن للألم قوي المفعول)، سيرترالين، وسائل منع الحمل التي تؤخذ عن طريق الفم، ديلتيازيم (يستخدم لعلاج ضغط الدم المرتفع)، المضادات الحيوية الماكروليدية مثل إريثروميسين وكلاريثروميسين، سيميتيدين (يستخدم لتقليل إنتاج الأحماض في المعدة).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد تقلل الأدوية التالية من تأثير ألبرازولام:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، فينوباربيتال، فينيتوين (يستخدم لعلاج الصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يستخدم لعلاج السل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (دواء عشبي يستخدم لعلاج الاكتئاب).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول ديجوكسين (المستخدم لعلاج فشل القلب)، حيث قد يلزم تعديل جرعة زاناكس أو بدء مراقبة الحالة بشكل مستمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول زاناكس مع الطعام والشراب</strong></p><p dir="RTL">يمكن أن تزيد الكحوليات من حدة تأثير مركبات البنزوديازيبين، خصوصًا الذهول. لذلك يجب عليك عدم شرب الكحوليات أثناء العلاج بزاناكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء. لا ينصح باستخدام مركبات البنزوديازيبين أثناء الحمل والرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير زاناكس على القيادة واستخدام الآلات</strong></p><p dir="RTL">نظرًا لأن مركبات البنزوديازيبين قد تؤثر على قدرتك على القيام برد فعل (وخاصةً وقت رد فعلك)، فلا ينصح بالقيادة ولا استخدام أدوات أو آلات معينة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة حول بعض مكونات زاناكس</strong></p><p dir="RTL"><strong>يحتوي زاناكس </strong><strong>٠</strong><strong>,٥</strong><strong> ملجم و</strong>١<strong> ملجم على الألومنيوم.</strong></p><p dir="RTL">إذا كنت مصابًا بالحساسية تجاه الألومنيوم، فلا تتناول أقراص زاناكس ٠,٥ ملجم و١ ملجم. وأقراص زاناكس الأخرى لا تحتوي على الألومنيوم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي زاناكس على اللاكتوز.</strong></p><p dir="RTL">تحدث مع طبيبك قبل تناول زاناكس إذا كنت تعلم أنك تعاني من عدم تحمل السكريات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p>في بداية العلاج، قد تشعر بالنعاس قليلًا، وعادةً ما يقل هذا مع مواصلة العلاج. استشر طبيبك إذا حدث هذا التأثير&nbsp;</p><p>علاج أعراض القلق</p><p dir="RTL">الجرعة (الكمية) المُوصى بها للمرضى الأكبر من ١٨ عامًا هي ٠,٢٥ ملجم إلى ٠,٥ ملجم ثلاث مرات في اليوم، وتصل إلى ٤ ملجم في اليوم بحد أقصى.</p><p dir="RTL">يجب تقليل الجرعة إلى أقل جرعة فعالة ممكنة، خاصة في حالة المرضى كبار السن والضعفاء، على سبيل المثال ٠,٢٥ ملجم مرتين إلى ثلاث مرات في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احرص دائمًا على اتباع تعليمات طبيبك بعناية.</p><p dir="RTL">إذا كانت لديك أسئلة إضافية تتعلق باستخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>مدة العلاج:</em></p><p dir="RTL">قد يزداد خطر الاعتماد على الدواء أو سوء استخدامه مع زيادة الجرعة ومدة العلاج. لذلك سيصف الطبيب أقل جرعة فعالة لأقصر مدة، وسيقوم بانتظام بإعادة تقييم الحاجة إلى استمرار العلاج (انظر القسم ٢ &quot;الاحتياطات عند استعمال زاناكس&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدة العلاج القصوى يجب ألا تتجاوز أسبوعين إلى ٤ أسابيع. لا يوصى بالعلاج طويل الأمد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك بالمدة التي يجب عليك تناول زاناكس خلالها. لا توقف العلاج قبل الأوان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من زاناكس</strong></p><p dir="RTL">إذا تناولت كمية أكبر من اللازم من زاناكس، فاتصل بطبيبك أو الصيدلي أو مركز مكافحة السموم فورًا.</p><p dir="RTL">لا تعطِ المريض أي شيء يشربه إذا لم يكن واعيًا تمامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">معلومات للطبيب</p><p dir="RTL">في حالة حدوث تسمم شديد مصحوبًا بغيبوبة أو فشل تنفسي، يمكن إعطاء فلومازينيل عن طريق الوريد كترياق.</p><p dir="RTL">يُمنع استخدام فلومازينيل كترياق في الحالات التالية:</p><p dir="RTL"><em>- عند استخدام مضادات الاكتئاب ثلاثية الحلقات</em></p><p dir="RTL"><em>- في حالة الاستخدام المتزامن مع الأدوية المسببة ل</em><em>نوبات </em><em>الاختلاج</em></p><p dir="RTL">- عند وجود اختلالات في رسم القلب (ECG)، مثل استطالة مركّب QRS أو فترة QT (مما يثير الاشتباه في استخدام مضادات الاكتئاب ثلاثية الحلقات بشكل متزامن).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة زاناكس</strong></p><p dir="RTL">إذا نسيت تناول إحدى الجرعات في موعدها المعتاد، فتناولها بمجرد أن تتذكرها ما لم يكن قد حان موعد تناول جرعتك التالية. في هذه الحالة، تخط الجرعة المنسية واستمر في العلاج كالمعتاد. لا تتناول جرعة مضاعفة إذا نسيت الجرعة السابقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول زاناكس</strong></p><p dir="RTL">لا توقف العلاج فجأة، لأنه يجب تقليل الجرعة بشكل تدريجي بعد استشارة طبيبك. إذا أوقفت العلاج فجأة، فقد تحدث أعراض انسحاب مثل المزاج السيء، والأرق، والتقلصات، والغثيان، والعرق، ونوبات الاختلاج، والهذيان، وخاصة مع المرضى الذين يتلقون جرعات عالية من العلاج.</p><p dir="RTL">لذلك سيقوم طبيبك بتقليل الجرعة تدريجيًا في نهاية مدة العلاج. ويُحدد معدل تقليل الجرعة على أساس فردي، لأن إيقاف العلاج تدريجيًا يعتمد على عوامل كثيرة (مثل مدة العلاج وجرعتك اليومية). اسأل طبيبك عن كيفية تقليل جرعتك تدريجيًا.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاطرحها على طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ارتبطت الآثار الجانبية التالية بالعلاج بألبرازولام لدى المرضى المشاركين في التجارب الإكلينيكية المراقبة، إلى جانب الآثار الجانبية المبلّغ عنها بعد التسويق (*):</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا (قد تصيب أكثر من شخص واحد من بين كل </strong>١٠<strong> أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهدئة (النوم)، النعاس، فقدان القدرة على تنسيق الحركات، ضعف الذاكرة، صعوبة في الكلام (عسر التلفظ)، الدوار، الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك، جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق، التهيج</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تصيب ما يصل إلى شخص واحد من بين كل </strong>١٠<strong> أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك، التوهان، انخفاض الرغبة الجنسية، القلق، الأرق، العصبية، زيادة الرغبة الجنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات التوازن، اضطرابات التناسق، اضطرابات التركيز، الحاجة غير الطبيعية إلى النوم (فرط النوم)، الخمول (ضعف شديد)، الرعاش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيم الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد (التهاب الجلد)*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخلل الوظيفي الجنسي*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن، زيادة الوزن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهوس* (فرط النشاط واستثارة غير طبيعية) (انظر القسم ٢: الاحتياطات عند استعمال زاناكس)، الهلاوس*، الغضب*، الهياج*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلس البول*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام الدورة الشهرية*</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية ذات معدل التكرار غير المعروف:</strong></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>اضطرابات</em><em> الجهاز العصبي المستقل*، </em>ضعف التوتر العضلي (خلل التوتر)*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم الوعائي*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية تجاه الضوء*</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>زيادة إنتاج البرولاكتين*</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>الهوس الخفيف*، العدوانية*، العدائية*، الأفكار غير الطبيعية*، فرط النشاط النفسي الحركي*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات المعدية المعوية*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد (التهاب الكبد الوبائي)*، الخلل الوظيفي بالكبد*، اليرقان*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس البول*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الضغط داخل العين*</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>التورم الطرفي*</p><p dir="RTL">&nbsp;</p><p dir="RTL">وأبلغ أيضًا عن الآثار الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة (قد تصيب ما يصل إلى شخص واحد من بين كل </strong>١٠٠٠<strong> شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الركود الصفراوي (انخفاض إفراز الصفراء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ندرة المحببات (نقص بعض خلايا الدم البيضاء في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثبيط التنفس لدى المرضى المصابين باضطرابات تنفسية مزمنة غير محددة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية أو تفاعلات حساسية شديدة يُحتمل أن تكون مهددة للحياة (التأق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات متقطعة في الإباضة وزيادة حجم الثدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القهم (فقدان الشهية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">وأبلغ عن حدوث الآثار الجانبية التالية لمركبات البنزوديازيبين بشكل نادر جدًا أو استثنائي جدًا: الإرهاق، علامات على جنون الارتياب، الاعتماد النفسي والجسدي، أعراض الانسحاب (الصداع، ألم العضلات، القلق الشديد، التهيج، الشعور بالانفصال عن الواقع (تبدد الواقع)، تبدد الشخصية (فقدان الشعور بالواقع الجسدي أو العقلي)، ضعف السمع، الشعور بالتيبس والتنميل في الأطراف، فرط الحساسية تجاه الضوضاء والتلامس الجسدي، نوبات الصرع).</p><p dir="RTL">عند إيقاف العلاج قد تحدث أعراض انسحاب (ظواهر &quot;ارتدادية&quot;) مثل الأرق والقلق، بالإضافة إلى التقلبات المزاجية، والقلق، واضطرابات النوم، والتهيج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:385px"><tbody><tr><td style="vertical-align:top; width:382px"><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال بالهيئة العامة للغذاء والدواء (SFDA): ١٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><ul><li dir="RTL">دول الخليج الأخرى</li></ul><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:391px"><tbody><tr><td style="vertical-align:top; width:388px"><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">خزنه عند درجة حرارة أقل من ٢٥ درجة مئوية.</p><p dir="RTL">لا تستخدم زاناكس بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية بعد رمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">صلاحية المستحضر: ٣٦ شهر.</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكون الفعال هو ألبرازولام. يحتوي القرص الواحد على ٠,٢٥ ملجم أو ٠,٥ ملجم أو ١ ملجم من ألبرازولام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: لاكتوز، سليولوز بلوري مكروي، سيليكا غروية لا مائية، نشا الذرة، ستيارات المغنيسيوم ودوكوسات الصوديوم (٨٥ ٪) مع مسحوق بنزوات الصوديوم (١٥ ٪)، إريثروسين (E127) في صورة صبغة ليك الألومنيوم (في الأقراص التي تحتوي على ٠,٥ ملجم و١ ملجم فقط) وصبغة نيلية قرمزية (E132) في صورة صبغة ليك الألومنيوم (في الأقراص التي تحتوي على ١ ملجم فقط).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتوفر أقراص زاناكس في صورة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; أقراص بيضاء محززة بيضاوية الشكل تحتوي على ٠,٢٥ ملجم: عبوات تحتوي على ٥٠ قرصًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; أقراص وردية محززة بيضاوية الشكل تحتوي على ٠,٥ ملجم: عبوات تحتوي على ٥٠ قرصًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; أقراص أرجوانية محززة بيضاوية الشكل تحتوي على ١ ملجم: عبوات تحتوي على ٣٠ قرصًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق:</strong></p><p dir="RTL">أبجون اس ار ال، بولیفارد لا بلین 17 ، 1050 بروكسیل، بلجیكا.</p><p dir="RTL">بلجيكا&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة:</strong></p><p dir="RTL">سانيكو ان.في ، بلجيكا</p><p dir="RTL">بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تم</strong><strong> تعبئته وإطلاقه بواسطة</strong><strong>:</strong></p><p dir="RTL">فايزر إيطاليا اس.ار. ال ، إيطاليا</p><p dir="RTL">إيطاليا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XANAX 0,25 mg tablets
XANAX 0,5 mg tablets
XANAX 1 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XANAX 0,25 mg, 0,5 mg and 1 mg tablets 
XANAX Tablets contain 0,25 mg, 0,5 mg and 1 mg alprazolam, respectively, as active substance. 
Excipients with known effect:
Each 0,25 mg, 0,5 mg and 1 mg Tablet contains 96 mg lactose. 
For the full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets 
XANAX 0.25 mg white elliptic-oval divisible tablets
XANAX 0.5 mg pink elliptic-oval divisible tablets
XANAX 1 mg lavender-coloured elliptic-oval divisible tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>XANAX is indicated for short-term symptomatic treatment of anxiety in adults.</p><p>XANAX is only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Duration of treatment</u></p><p>XANAX should be used in the lowest possible effective dose, for the shortest possible time and for a maximum of 2-4 weeks. The need for continued treatment should be reassessed frequently. Long-term treatment is not recommended. The risk of dependence may increase with dose and duration of treatment (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p><u>XANAX divisible tablets</u>: The optimum dosage should be determined individually based on the severity of the symptoms and individual patient response. In the event of severe adverse effects with the initial dose, a dose reduction is necessary.</p><p>In the few patients who require a higher dose, the dosage should be increased gradually, starting with a higher dose in the evening, to avoid adverse effects. In general, patients who have not previously taken psychotropic agents will require a lower dose compared to those who have previously been treated with tranquillizers, antidepressants or hypnotics or compared to chronic alcoholics.</p><p>In order to prevent ataxia and oversedation, it is advisable to use the lowest effective dose. This is particularly important in elderly and/or debilitated patients.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Safety and efficacy of alprazolam in children and adolescents below the age of 18 years have not been established; therefore use of alprazolam is not recommended.</p><p>&nbsp;</p><p>SYMPTOMATIC TREATMENT OF ANXIETY</p><p>XANAX Tablets</p><p>Usual starting dose: varies from 0.25 mg to 0.5 mg three times daily.</p><p>Usual dose: The dose can be increased to suit the patient&rsquo;s needs to a maximal daily dose of 4 mg divided over multiple administrations.</p><p>&nbsp;</p><p>TREATMENT OF GERIATRIC OR DEBILITATED PATIENTS</p><p>XANAX tablets</p><p>Usual starting dose: 0.25 mg twice to three times daily.</p><p>Usual dose: If necessary, the dose can be increased gradually depending on tolerance.</p><p>&nbsp;</p><p>The starting dose should be reduced if side-effects occur.</p><p>&nbsp;</p><p>DISCONTINUATION OF TREATMENT</p><p>Since the treatment is symptomatic, the original symptoms may recur after discontinuation of treatment.</p><p>The dose must be gradually reduced to avoid withdrawal symptoms. The patient should be re-assessed regularly and the need to prolong treatment should be evaluated, certainly when the patient&rsquo;s symptoms are milder and might not require medicinal treatment. The general period of treatment should not exceed 2 to 4 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XANAX is contra-indicated in: 
•	myasthenia gravis 
•	hypersensitivity to alprazolam, to benzodiazepines or to any of the excipients listed in section 6.1.
•	severe respiratory insufficiency 
•	sleep apnoea syndrome 
•	severe hepatic insufficiency 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Risks from Concomitant Use with Opioids</strong></p><p>Concomitant use of benzodiazepines, including XANAX, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.</p><p>&nbsp;</p><p>Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe XANAX concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of XANAX than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking XANAX, prescribe a lower initial dose of the opioid and titrate based upon clinical response.</p><p>Advise both patients and caregivers about the risks of respiratory depression and sedation when XANAX is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined [see Drug Interactions].</p><p>&nbsp;</p><p><em>Duration of treatment</em></p><p>The duration of treatment should be as short as possible and not more than 2-4 weeks (see section 4.2). An extension of the treatment time beyond this must not be made without a reassessment of the situation.</p><p>&nbsp;</p><p>It may be appropriate to inform the patient on initiation of treatment that the treatment is time-limited and to explain exactly how the dosage will be gradually decreased. There is evidence to suggest that withdrawal symptoms may occur within the dosage interval when using short-acting benzodiazepines, especially at high doses. When long-acting benzodiazepines are used it is important to inform the patient that he/she should not change to a short-acting benzodiazepine, as withdrawal symptoms may then develop.</p><p>&nbsp;</p><p><em>Dependence</em></p><p>Addiction and physical and psychic dependence can occur with the use of benzodiazepines, including alprazolam. The risk of dependence increases with dose and duration of treatment; this risk is also greater in patients with a history of alcohol or drug abuse. Pharmacodependency may occur at therapeutic doses and/or in patients with no individualised risk factor. There is an increased risk of pharmacodependency with the combined use of several benzodiazepines regardless of the anxiolytic or hypnotic indication. Cases of abuse have also been reported.</p><p>&nbsp;</p><p><em>Withdrawal symptoms</em></p><p>Once dependence has developed, rapid tapering off or abrupt discontinuation of benzodiazepines, including alprazolam, can result in undesirable effects such as rebound phenomena or withdrawal symptoms (see section 4.8).&nbsp; These symptoms appear under the form of headaches, muscle pain, extreme anxiety, tension, agitation, confusion, irritability and insomnia.&nbsp; In severe cases the following symptoms may occur: derealisation, depersonalisation, hyperacusis, numbness and tingling of the extremities, hypersensitivity to light, noise and physical contact, hallucinations or epileptic seizures. These signs and symptoms, and the more severe forms in particular, are generally observed most frequently in patients after long-term treatment with excessive doses. However, withdrawal symptoms have also been reported after abrupt discontinuation of therapeutic doses of benzodiazepines.</p><p>During discontinuation of treatment, the dosage should be reduced therefore slowly in keeping with good medical practice (see section 4.2 Posology and method of administration &ndash; Discontinuation of treatment), particularly in epileptic patients.</p><p>&nbsp;</p><p><em>Amnesia</em></p><p>Benzodiazepines may induce anterograde amnesia. The condition occurs most often several hours after ingesting the product.</p><p>&nbsp;</p><p><em>Psychiatric and paradoxical reactions</em></p><p>Reactions like restlessness, agitation, irritability, aggressiveness, delusion, rages, nightmares, hallucinations, psychoses, inappropriate behaviour and other behavioural effects are known to occur when using benzodiazepines (see section 4.8). Should this occur, use of alprazolam should be discontinued. These reactions are more likely to occur in children and elderly.</p><p>&nbsp;</p><p><em>Tolerance</em></p><p>Some loss of the hypnotic effects of benzodiazepines may develop after repeated use for a few weeks.</p><p>Tolerance or dose increase are rarely observed with alprazolam, but can occur. Tolerance has been demonstrated for the sedative action, but not for the anxiolytic effect of alprazolam.</p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>Benzodiazepines and related products should be used with caution in elderly, due to the risk of sedation and/or musculoskeletal weakness that can promote falls, often with serious consequences in this population.</p><p>&nbsp;</p><p>In geriatric and debilitated patients it is advisable to use the lowest effective dose to prevent ataxia or oversedation.</p><p>&nbsp;</p><p>In patients with impaired renal or hepatic function the usual precautions should be taken.</p><p>&nbsp;</p><p>Safety and efficacy of alprazolam in children and adolescents below the age of 18 years have not been established; therefore use of alprazolam is not recommended.</p><p>&nbsp;</p><p>Suitable precautions should be taken in patients with acute closed angle glaucoma.</p><p>&nbsp;</p><p>Benzodiazepines and benzodiazepine-like agents should not be prescribed alone to treat depression as they may precipitate or increase the risk of suicide. Therefore XANAX should be used with caution and the prescription size should be limited in patients with signs and symptoms of a depressive disorder or suicidal tendencies. Episodes of hypomania and mania have been reported in association with the use of alprazolam in patients with depression.</p><p>&nbsp;</p><p>Benzodiazepines should be used with extreme caution in patients with a history of alcohol or drug abuse (see 4.5 Interaction with other medicinal products and other forms of interactions).</p><p>&nbsp;</p><p>Lactose: the tablets and prolonged-release tablets contain lactose. Patients with galactose intolerance, total lactase deficiency or glucose-galactose malabsorption (rare hereditary problems) should not take this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Benzodiazepines and Other Central Nervous System (CNS) Depressants </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical Impact</strong></p></td><td style="vertical-align:top"><p><strong>Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, respiratory depression, profound sedation, coma and Death. </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Intervention</strong></p></td><td style="vertical-align:top"><p><strong>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation (see warning and precautions)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Examples </strong></p></td><td style="vertical-align:top"><p><strong>Benzodiazepines and other Sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>Benzodiazepines, including alprazolam, have an additive depressant effect on the central nervous system (CNS) when used in combination with other psychotropic agents, anticonvulsives, antihistaminics, alcohol and other agents with an effect on the CNS.</p><p>Concomitant intake with alcohol is not recommended. Alprazolam should be used with caution when combined with CNS depressants. Enhancement of the central depressive effect may occur in cases of concomitant use with antipsychotics (neuroleptics), hypnotics, anxiolytics/sedatives, antidepressant agents, narcotic analgesics, anti-epileptic products, anesthetics and sedative antihistamines. In the case of narcotic analgesics enhancement of the euphoria may also occur leading to an increase in psychic dependence.</p><p>&nbsp;</p><p>No effects on prothrombin time and warfarin plasma levels have been observed.</p><p>&nbsp;</p><p>Increased digoxin concentrations have been reported when alprazolam was given, especially in elderly (&gt;65 years of age). Patients who receive alprazolam and digoxin should therefore be monitored for signs and symptoms related to digoxin toxicity.</p><p>&nbsp;</p><p>Pharmacokinetic interactions can occur when alprazolam is administered in combination with drugs that interfere with its metabolism.</p><p>&nbsp;</p><p><em>CYP3A4 inhibitors</em></p><p>Drugs that inhibit certain hepatic enzymes (in particular the cytochrome P450 3A4 enzyme system) can increase the concentration of alprazolam and potentiate its effect. Data from clinical studies with alprazolam, in vitro studies with alprazolam, and clinical studies with drugs metabolized similarly to alprazolam provide evidence for varying degrees of interaction and possible interaction with alprazolam for a number of drugs. Based on the degree of interaction and the type of data available, the following recommendations are made:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Combined use with ketoconazole, itraconazole or other azole-like antifungal agents is not recommended.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution and possibly a dose reduction are recommended in case of combined use with nefazodon, fluvoxamine and cimetidine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution is required in the event of combined use with fluoxetine, propoxyphene, oral contraceptives, sertraline, diltiazem or macrolide antibiotics such as erythromycin and clarithromycine.</p><p>&nbsp;</p><p><em>CYP3A4 Inducers</em></p><p>Since alprazolam is metabolized by CYP3A4, inducers of this enzyme (e.g, carbamazepine, phenobarbital, phenytoin, rifampicin and St John&rsquo;s Wort) could cause decreased effect of alprazolam</p><p>Interactions involving HIV protease inhibitors (e.g. ritonavir) and alprazolam are complex and time dependent. Short term, low doses of ritonavir resulted in a large impairment of alprazolam clearance, prolonged its elimination half-life and enhanced clinical effects. However, upon extended exposure to ritonavir, CYP3A induction offset this inhibition. This interaction will require a dose-reduction or discontinuation of alprazolam treatment.</p><p>&nbsp;</p><p>Mean increases of respectively 31 % and 20 % of the steady-state plasma levels of imipramine and desipramine have been reported during concurrent administration of XANAX up to 4 mg daily. The clinical significance of these changes has not yet been established.</p><p>&nbsp;</p><p>Interactions with isoniazide or rifampicin have not been evaluated.</p><p>&nbsp;</p><p>No changes in alprazolam kinetics have been noted during concurrent administration of propranolol or disulfiram.</p><p>&nbsp;</p><p>Although it has never been described with alprazolam, there is an increased risk of psychosis when benzodiazepines are used in combination with valproic acid.</p><p>&nbsp;</p><p>Theophyllin antagonizes the effect of benzodiazepines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>Alprazolam should not be used during pregnancy unless the clinical condition of the woman requires treatment with alprazolam. If alprazolam is used during pregnancy, or the patient becomes pregnant while taking alprazolam, the patient should be apprised of the potential hazard to the fetus.</p><p>&nbsp;</p><p>When alprazolam is prescribed to a woman of childbearing age, she should be warned to notify her physician if she wishes to become pregnant or if she is pregnant, so the physician can decide to discontinue treatment.</p><p>&nbsp;</p><p>Benzodiazepines pass the foetoplacental barrier. Children of patients who have taken benzodiazepines during pregnancy may present malformations. This has not been quantified for alprazolam.</p><p>Benzodiazepine treatment at high dose, during the second and/or the third trimester of pregnancy, has revealed a decrease of fetal active movements and a variability of fetal cardiac rhythm.</p><p>When the product is administered for medical reasons during the last phase of pregnancy or during delivery, hypothermia, axial hypotonia, sucking troubles leading to a poor weight gain may be observed. At high doses, respiratory depression or apnea and hypothermia may appear in the newborn. These signs are reversible but they may last from 1 up to 3 weeks, according to the half life of the product. Since infants whose mother took benzodiapines chronically during pregnancy may have developed physical dependence, withdrawal symptoms can occur in the postnatal development. They result in hyperexcitability, agitation and tremor observed a few days after birth. The apparition of withdrawal symptoms after birth depends on the half life of the substance.</p><p>&nbsp;</p><p>The data concerning teratogenicity and effects on postnatal development and behavior following benzodiazepine treatment are inconsistent. A large amount of data based on cohort studies indicate that first trimester exposure to benzodiazepines is not associated with an increase in the risk of major malformation. However, some early case-control epidemiological studies have found a twofold increased risk of oral clefts.</p><p>&nbsp;</p><p>If alprazolam treatment is necessary during the last part of pregnancy, high doses should be avoided and withdrawal symptoms and/or floppy infant syndrome should be monitored in newborn,</p><p>&nbsp;</p><p><em>Breast-feeding</em></p><p>Alprazolam is excreted in breast milk. A risk for newborns/infants cannot be excluded. Although the use of benzodiazepines is not recommended during lactation, a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from alprazolam therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman&nbsp;please refer to Section 4.4 for information on the discontinuation of alprazolam therapy.</p><p>&nbsp;</p><p><em>Fertility</em></p><p>Alprazolam did not impair fertility in rats up to the highest dose tested of 5 mg/kg (Human Equivalent Dose of 0.8 mg/kg), about 5 times the maximum recommended daily human exposure (see section 5.3 Preclinical Safety Data).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other substances that act on the central nervous system, patients receiving treatment with XANAX should be warned not to drive a vehicle or operate dangerous machinery until it has been established that they do not become impaired while receiving the drug. For the same reason these patients should be warned not to combine the use of alcohol and CNS depressants during treatment with XANAX.</p><p>Sedation, amnesia, impaired concentration and impaired muscular function may adversely affect the ability to drive or to use machines. If insufficient sleep duration occurs, the likelihood of impaired alertness may be increased (see section 4.5 Interaction with other medicinal products and other forms of interactions).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most annoying adverse effects of XANAX are due to an extension of the pharmacological activity of alprazolam.</p><p>Whether or not certain undesirable effects occur depends totally on the patient&rsquo;s individual sensitivity and the dose administered. Potential adverse effects are usually observed at the start of treatment and usually disappear when the treatment is continued or when the dose is reduced.</p><p>&nbsp;</p><p>Adverse reactions reported as more than an isolated case are listed below, by system organ class and by frequency. Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100, &lt; 1/10), uncommon (&ge; 1/1,000, &lt; 1/100), rare (&ge; 1/10,000, &lt; 1/1,000); very rare (&lt; 1/10000) and not known (cannot be estimated from available data).</p><p>&nbsp;</p><p>Undesirable effects associated with alprazolam therapy in patients participating in controlled clinical studies and with post-marketing experience are as follows:</p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><thead><tr><td colspan="7" style="vertical-align:top"><p>Adverse Reactions Table</p></td></tr><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very Common</p><p>&ge; 1/10</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p><p>&ge; 1/100</p><p>to &lt; 1/10</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&ge; 1/1 000 to &lt;</p><p>1/100</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p><p>&ge; 1/10 000 to &lt;</p><p>1/1 000</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very Rare</p><p>&lt; 1/10 000</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Frequency</p><p>not known</p><p>(cannot be estimated from available data)</p><p>&nbsp;</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Endocrine Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperprolactinaemia*</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>Confusional state, disorientation, decreased libido , anxiety, insomnia, nervousness, increased libido</p></td><td style="vertical-align:top"><p>Mania* <strong>(see section</strong> <strong>4.4 Special warnings and precautions for use</strong>), hallucination*, anger*, agitation*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypomania*<strong>, </strong>aggression*, hostility*, abnormal thinking *, psychomotor hyperactivity*</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>Sedation, somnolence. ataxia, memory impairment, dysarthria,&nbsp; dizziness, headache</p></td><td style="vertical-align:top"><p>Balance disorder, abnormal coordination, disturbance in attention, hypersomnia, lethargy,<strong> </strong>tremor</p></td><td style="vertical-align:top"><p>Amnesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Autonomic nervous system imbalance*, dystonia*</p></td></tr><tr><td style="vertical-align:top"><p>Eye Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blurred vision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>Constipation, dry mouth</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gastrointestinal disorder*</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis*, hepatic function abnormal*, jaundice*</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dermatitis*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema*, photosensitivity reaction*</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, Connective Tissue and Bone Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Incontinence*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary retention*</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive System and Breast Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sexual dysfunction*&nbsp;</p></td><td style="vertical-align:top"><p>Menstruation irregular*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td><td style="vertical-align:top"><p>Fatigue, irritability</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema peripheral *</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased weight, increased weight</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased intraocular pressure *</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>*ADR identified post-marketing</p><p>&nbsp;</p><p>The following additional undesirable effects have been reported:</p><p>&nbsp;</p><p>Hepatobiliary disorders</p><p>Rare: cholestasis.</p><p>&nbsp;</p><p>Blood and lymphatic system disorders</p><p>Rare: agranulocytosis.</p><p>&nbsp;</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Rare: respiratory depression in patients with chronic atypical respiratory conditions.</p><p>&nbsp;</p><p><em>Immune System Disorder</em></p><p>Rare: hypersensibility (allergic reactions or anaphylaxis).</p><p>&nbsp;</p><p>Renal and urinary disorders</p><p>Rare: sporadic ovulation disorders and gynaecomastia.</p><p>&nbsp;</p><p>Gastrointestinal disorders</p><p>Rare: anorexia.</p><p>&nbsp;</p><p>During treatment with high doses&nbsp; the following adverse effects were noted more frequently compared to placebo: sedation, somnolence, fatigue, ataxia, impaired co-ordination, speech disorders. The following adverse effects were observed less frequently: mood changes, gastrointestinal symptoms, dermatitis, memory disorders, sexual dysfunction, cognitive disorders and confusion.</p><p>&nbsp;</p><p>OTHER EFFECTS DUE TO THE USE OF BENZODIAZEPINES</p><p>- paradoxical reactions such as irritability, stimulation, anger, aggressive or hostile behaviour, increased agitation, nervousness, anxiety or insomnia. In many of the spontaneous case reports of adverse behavioral effects, patients were receiving other CNS drugs concomitantly and/or were described as having underlying psychiatric conditions.&nbsp; Patients who have borderline personality disorder, a prior history of violent or aggressive behavior, or alcohol or substance abuse may be at risk for such events.&nbsp; Instances of irritability, hostility and intrusive thoughts have been reported during discontinuance of alprazolam in patients with post-traumatic stress disorder.</p><p>- psychic and physical dependence.</p><p>- withdrawal symptoms:</p><p>Once physical dependence has developed, abrupt cessation of treatment can be associated with withdrawal symptoms. These can vary from headache, muscle pain, extreme anxiety, tension, agitation, confusion, irritability to derealization, depersonalisation, impaired hearing, stiffening and tingling of the limbs, hypersensitivity to light, noise and physical contact, hallucinations or epileptic seizures.</p><p>Rebound phenomena such as insomnia and anxiety can occur when treatment is discontinued. Mood changes, anxiety, sleep disorders and agitation may also occur in these circumstances.</p><p>Benzodiazepine abuse has been reported.</p><p>Severe symptoms in particular are observed more frequently in patients on long-term high dose treatment. These withdrawal symptoms have also been observed when treatment was withdrawn rapidly or discontinued abruptly. Gradual dose reduction is therefore advisable when treatment is discontinued.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p><br />Reporting suspected adverse reactions after marketing authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p><strong>&nbsp;T</strong><strong>o report any side effects</strong></p><ul><li><strong>Saudi Arabia</strong></li></ul><table border="1" cellspacing="0" cellpadding="0" style="width:306px"><tbody><tr><td style="vertical-align:top; width:303px"><p>The National Pharmacovigilance Center (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other </strong><strong>GCC States</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Please contact the relevant competent authority.</strong></p></td></tr></tbody></table></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of XANAX overdosage is usually manifested by degrees of central nervous system depression ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, mental confusion and lethargy. In more serious cases, symptoms may include ataxia, hypotonia, hypotension, respiratory depression, rarely coma and very rarely death.</p><p>Although a benzodiazepine overdose is not usually life-threatening, it is always necessary to bear in mind the possibility that CNS depressants such as alcohol or barbiturates have been taken and the potential underlying pathology should be considered. In the management of any overdose, it should be borne in mind that other agents may have been taken simultaneously. Treatment should be adapted accordingly and consists mainly in induction of vomiting (within one hour) if the patient is conscious or gastric lavage undertaken with the airway protected if the patient is unconscious. If there is no advantage in emptying the stomach, activated charcoal should be given to reduce absorption. Afterwards, an osmotic laxative can be administered. Special attention should be paid to supporting respiratory and cardiovascular functions in intensive care. In case of coma, treatment is mainly symptomatic, thereby avoiding complications such as asphyxiation due to ptosis of the tongue or aspiration of gastric contents. Intravenous fluid administration is required to prevent dehydration. When other sedatives have been taken in combination, it is of primordial importance to support vital functions. It is known that the effect due to ingestion of a very large dose can persist for a long time. Forced diuresis or haemodialysis is of limited use.</p><p>In case of a severe intoxication with coma or respiratory insufficiency, IV administration of flumazenil can be used as an antidote. The use of flumazenil as an antidote is contra-indicated in the following situations:</p><p>- Use of tricyclic antidepressants</p><p>- Concurrent use of drugs that induce seizures</p><p>- ECG anomalies such as a prolonged QRS interval or QT interval (suggestive of concurrent use of tricyclic antidepressants).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: derivatives of benzodiazepines, ATC code: N05B A12.</p><p>XANAX contains triazolobenzodiazepine. All benzodiazepines have qualitatively similar properties: anxiolysis, hypnosedation, myorelaxation, anticonvulsion. However, there are quantitative pharmacokinetic differences, which have resulted in various fields of application.</p><p>In general it is accepted that the action of benzodiazepines is based upon potentiation of neural inhibition, mediated by gamma-aminobutyric acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>XANAX tablets</p><p>Maximal plasma levels are reached one to two hours after oral administration of XANAX tablets.</p><p><br /><u>ALPRAZOLAM</u></p><p>The half-life of alprazolam is between 12 and 15 hours and is 16 hours on average in elderly patients.</p><p>Alprazolam is mainly oxidized. The principal metabolites of alprazolam are alpha-hydroxy-alprazolam and a benzophenone derivative. The plasma levels of these metabolites are extremely low. The biological activity of alpha-hydroxy-alprazolam is about the half of that of alprazolam. Their half-lives are of the same order of magnitude as that of alprazolam.</p><p>The benzophenone derivative is almost inactive.</p><p>Alprazolam and its metabolites are mainly eliminated via urine.</p><p>In vitro, 80 % of alprazolam is bound to serum proteins.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mutagenesis, Carcinogenesis, Fertility, and Ocular Effects</u></p><p>Alprazolam was not mutagenic in the in vitro Ames test.&nbsp; Alprazolam did not produce chromosomal aberrations in the in vivo micronucleus assay in rats up to the highest dose tested of 100 mg/kg.</p><p>No evidence of carcinogenic potential was observed during 2-year bioassay studies of alprazolam in rats at doses up to 30 mg/kg (Human Equivalent Dose of 4,8 mg/kg) and in mice at doses up to 10 mg/kg (Human Equivalent Dose of 0,8 mg/kg, values that are about 28 times and 5 times, respectively, the maximum recommended daily human exposure of 10 mg (0,17 mg/kg).</p><p>Alprazolam did not impair fertility in rats up to the highest dose tested of 5 mg/kg (Human Equivalent Dose of 0.8 mg/kg), about 5 times the maximum recommended daily human exposure.</p><p>When rats were treated orally with alprazolam at 3, 10, and 30 mg/kg (Human Equivalent Dose range of 0,5 mg/kg to 4,8 mg/kg) for 2 years, which is 3 to 28 times the maximum daily human exposure, a tendency for a dose related increase in the number of cataracts (females) and corneal vascularization (males) was observed.&nbsp; These lesions did not appear until after 11 months of treatment.</p><p>During toxicity studies with repeated dosing over 12 months in dogs, seizures appeared with doses of 3 mg/kg (Human Equivalent Dose of 1,7 mg/kg) or more, corresponding to about 10 times the maximum daily human exposure.&nbsp; Duration and incidence of the seizure episodes were dose-dependent and some of them were fatal.&nbsp; The significance for humans is not evident.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>XANAX 0.25 mg, 0.5 mg and 1 mg tablets</u></p><p>The excipients are: lactose, microcrystalline cellulose, colloidal anhydrous silica, maize starch, magnesium stearate and sodium docusate (85 %) - sodium benzoate (15 %) powder. The tablets with 0.5 mg alprazolam also contain the colouring agent erythrosine aluminium laque (E 127). The tablets with 1 mg also contain the colouring agents erythrosine (E 127) aluminium laque and carmin indigo (E 132).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XANAX tablets: 36 months.
Do not use XANAX after the expiry date which is stated on the Carton / Blister label after “EXP”. The expiry date refers to the last day of that month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>Store below 25&ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>XANAX divisible tablets:</p><p>- tablets containing 0.25 mg: 50 tablets</p><p>- tablets containing 0.5 mg: 50 tablets</p><p>- tablets containing 1.0 mg: 30 tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER 
Upjohn SRL, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium.

MANUFACUTRED BY
Sanico N.V., Belgium

PACKED & RELEASED BY
Pfizer Italia S.R.I
Ascoli Piceno - Italy

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>